Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765500 · ClinicalTrials.gov registry record · Phase 2
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
A Phase 2 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 3
- Study locations
NCT05765500 is a Phase 2 study of Prostate Cancer and Prostatic Neoplasms that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 110 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05765500, a Phase 2 study of Prostate Cancer and Prostatic Neoplasms, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Conditions Studied
Interventions
- DRUG Relugolix
- DRUG Leuprolide
Study Locations (3)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute at Foxborough - Foxborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05765500
The ClinicalTrials.gov registry entry for NCT05765500 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Relugolix is the first listed.
NCT05765500 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05765500 about?
NCT05765500 is a clinical study titled "RecoverPC: Relugolix vs GnRH Agonist in Quality of Life". This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used ...
What is the current status of trial NCT05765500?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2024-02-12. Estimated completion is 2028-01-01.
What conditions does trial NCT05765500 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT05765500?
The interventions under investigation include: Relugolix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT05765500?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05765500 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.